Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.European CHMP issues positive opinion recommending Suliqua for approval
CHMP recommended the use of Suliqua in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycemic control when this has not been
CHMP recommended the use of Suliqua in combination with metformin for the treatment of adults with type 2 diabetes mellitus to improve glycemic control when this has not been
The acquisition will mark Eagle’s entry into biologics, the fastest growing sector of the pharmaceuticals market, and will allow the Company to apply its proven market strategy to
Metformin DR is an investigational product designed to target metformin delivery to the lower small intestine, where it is minimally absorbed yet elicits robust glucose lowering effects. The
Under the terms of the agreement, the companies may elect to supply drug only or supply drug and share development costs on a study-by-study basis. The first study
emlidy has a boxed warning in its product label regarding the risks of lactic acidosis/severe hepatomegaly with steatosis and post-treatment severe acute exacerbation of hepatitis B. See below
The primary endpoints of the ARISE-2 trial are the change in ocular discomfort and the change in inferior corneal staining at baseline (prior to first dose) and at
The Patent Cooperation Treaty (PCT) is an international patent law treaty, which provides a unified procedure for filing patent applications to protect inventions in each of its member
Sorrento acquired approximately 72% of the outstanding common stock of SCILEX for a net purchase price of up to approximately $47.6m, payable in a combination of cash and
The platform is based on myxoma virus, a poxvirus that has been shown to have beneficial features for treating cancers. A major advantage of the myxoma virus is
Data from the company's Phase 3 sickle cell disease trial demonstrated a reduction in the frequency of sickle cell crises and hospitalizations, as well as a reduction in